PRKAA2

protein kinase AMP-activated catalytic subunit alpha 2

The protein encoded by this gene is a catalytic subunit of the AMP-activated protein kinase (AMPK). AMPK is a heterotrimer consisting of an alpha catalytic subunit, and non-catalytic beta and gamma subunits. AMPK is an important energy-sensing enzyme that monitors cellular energy status. In response to cellular metabolic stresses, AMPK is activated, and thus phosphorylates and inactivates acetyl-CoA carboxylase (ACC) and beta-hydroxy beta-methylglutaryl-CoA reductase (HMGCR), key enzymes involved in regulating de novo biosynthesis of fatty acid and cholesterol. Studies of the mouse counterpart suggest that this catalytic subunit may control whole-body insulin sensitivity and is necessary for maintaining myocardial energy homeostasis during ischemia.

provided by RefSeq

Biological Domains

Apoptosis, Autophagy, Epigenetic, Lipid Metabolism, Metal Binding and Homeostasis, Mitochondrial Metabolism, Oxidative Stress, Proteostasis, Structural Stabilization, Synapse

Pharos Class

Tchem

Also known as

ENSG00000162409 (Ensembl Release 115)

UNIPROTKB P54646

AMPK, AMPK2, AMPKa2, PRKAA

Summary of Evidence

This tab shows an overview of how the selected gene is associated with AD.

  • Genetic Association with LOAD

    Indicates whether or not this gene shows significant genetic association with Late Onset AD (LOAD) based on evidence from multiple studies compiled by the ADSP Gene Verification Committee
    False

  • Brain eQTL

    Indicates whether or not this gene locus has a significant expression Quantitative Trait Locus (eQTL) based on an AMP-AD consortium study
    True

  • RNA Expression Change in AD Brain

    Indicates whether or not this gene shows significant differential expression in at least one brain region based on AMP-AD consortium work. See ‘EVIDENCE’ tab.
    True

  • Protein Expression Change in AD Brain

    Indicates whether or not this gene shows significant differential protein expression in at least one brain region based on AMP-AD consortium work. See ‘EVIDENCE’ tab.
    False

  • Nominated Target

    Indicates whether or not this gene has been submitted as a nominated target to Agora.
    False

AD Risk Scores

About AD Risk Scores

The TREAT-AD Center at Emory-Sage-SGC has developed a Target Risk Score (TRS) to objectively rank the potential involvement of specific genes in AD. The TRS is derived by summing two component risk scores, the Genetic Risk Score and the Multi-omic Risk Score, each of which is derived from a meta-analysis of multiple harmonized data sets. More information about the methodology used to define these risk scores is available here.

AD Risk Scores for PRKAA2

The TRS for PRKAA2, along with the component Genetic and Multi-omic Risk Scores, is shown here. The scores for PRKAA2 are superimposed on the genome-wide score distributions. If No Data is Currently Available is displayed for a score, that score was not calculated for PRKAA2.

Biological Domain Classification

About Biological Domains

A biological domain represents a standardized area of biology defined by a set of discrete, biologically coherent GO terms. The TREAT-AD Center at Emory-Sage-SGC has defined nineteen biological domains associated with AD, and objectively mapped genes to those biological domains using GO term annotations. More information about the methodology used to define AD biological domains, and to generate genome-wide biological domain mappings, is available here.

Biological Domains for PRKAA2

Select a biological domain on the left to see the list of GO terms that link PRKAA2 to it on the right. The percentage value displayed next to the currently selected biological domain indicates the proportion of PRKAA2's total unique GO terms that map to the biological domain. The ratio displayed on the right indicates how many of the biological domain's total GO terms PRKAA2 is annotated with.